From the Editor

TON September 2015 Vol 8 No 5 - From the Editors
Beth Faiman, PhD, APRN-BC, AOCN
Editor in Chief

In this month’s issue of The Oncology Nurse-APN/PA (TON), we wrap up our coverage of the news from the recent Oncology Nursing Society (ONS) 40th Annual Congress and the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO).

At ONS, Anne Katz, RN, PhD, discussed how young adults with cancer are a unique population with special needs. She noted, “Three things are important in dealing with them: communication, communication, communication.” Mariana Chavez-MacGregor, MD, informed listeners that approximately 40% of patients with breast cancer treated with anthracyclines do not receive NCCN guideline–adherent prophylaxis for chemotherapy-induced vomiting. Laurie Farrell, NP, addressed nurses and advanced nurse practitioners about management options with obinutuzumab for patients with chronic lymphocytic leukemia.

Be sure to read our cancer center profile with Kathy Wilkinson, RN, BSN, OCN. Then pick up your copy of the TON July issue or go to the TON website (www.TheOncologyNurse.com) to get more information about Kathy’s ONS poster presentation on a strategy that utilized a dyad of disease-specific clinical trial nurses and disease-specific nurse navigators to boost enrollment in clinical trials at the Billings Clinic Cancer Center.

Our ASCO coverage includes a discussion of the basics of immunotherapy, including treatment response patterns, mechanisms of action, and management of side effects. We also present an interview with Jennifer Temel, MD, who talks about the potential role of anamorelin, a drug in phase 3 clinical trials. Anamorelin may help patients increase lean body mass and body weight.

October is National Breast Cancer Awareness Month. In Noteworthy Numbers, we present some information about a few organizations that sponsor programs in support of breast cancer, education, treatment, and research. Cristi Radford, in her Genetic Counseling column, updates readers about the research involving RECQL, which appears to be a new breast cancer susceptibility gene.

As always, we at TON want to hear about your ideas and opinions. Please be sure to visit our website, www.TheOncologyNurse.com, and tell us what topics you want to see covered in TON. We love to hear from you and we appreciate your feedback.

Related Items
From the Editors
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - May 2019, Vol 12, No 2 published on May 12, 2019 in From the Editors
From the Editors
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in From the Editors
From the Editor - TOP November 2018
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in From the Editors
From the Editor - TON September 2018
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in From the Editors
From the Editor - TOP August 2018
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in From the Editors
From the Editor - TON July 2018
Beth Faiman, PhD, APRN-BC, AOCN
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in From the Editors
From The Editor - TON March 2018
Beth Faiman, PhD, APRN-BC, AOCN
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in From the Editors
From the Editor
Beth Faiman, PhD, APRN-BC, AOCN
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in From the Editors
From The Editors - TOP November 2017
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in From the Editors
From the Editor
Beth Faiman, PhD, APRN-BC, AOCN
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Cancer Center Profile
Last modified: September 24, 2015